Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDX012 in MRD-positive AML
NCT05001451Phase 1Terminated
- Sponsor
- GammaDelta Therapeutics
- Start
- Aug 2021
- Primary completion
- Jun 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic variable delta 1 gamma-delta T cells in acute myeloid leukemia (AML), sponsored by GammaDelta Therapeutics. Primary endpoints: Incidence of treatment emergent adverse events and serious adverse events at 100 days, Incidence of treatment emergent clinically significant abnormal laboratory assessments at 100 days and 2 more. Started Aug 2021; status: terminated.
02
Drugs
allogeneic variable delta 1 gamma-delta T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05001451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001451.